PO.TB10.11 · 肿瘤生物学
结直肠癌中癌症相关成纤维细胞亚型异质性影响原发肿瘤侵袭
Cancer associated fibroblast subtype heterogeneity in colorectal cancer influences primary tumor invasion
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
肿瘤微环境(TME)对癌症进展的影响已成为一个重要研究领域,这在一定程度上由单细胞和空间技术的持续进步所推动,这些技术揭示 TME 具有高度异质性。癌症相关成纤维细胞(CAFs)是肿瘤基质的主要组成部分,已被分为若干亚型,每种亚型具有不同的功能和对肿瘤进展的影响。在这些亚型中,炎症性 CAFs(iCAFs)和肌成纤维细胞样 CAFs(myCAFs)通常由特征性生物标志物谱定义,并已被证明在肿瘤内具有不同的空间分布。然而,这些亚型在促进癌症进展(尤其是转移)方面的具体功能在很大程度上尚不清楚。鉴于转移性疾病预后不良,阐明这些 CAF 亚型在转移级联中所起的作用至关重要。为填补这一空白,我们建立了一个多样化的 CRC 患者来源组织样本及配对 CAF 细胞系的生物样本库。对患者组织进行的单细胞 RNA 测序鉴定出不同的 CAF 亚群。随后将这些转录特征应用于患者来源 CAF 细胞系的批量 RNA 测序,结果揭示出与 iCAF 和 myCAF 谱一致的表达模式。流式细胞术和分泌组分析进一步证实了亚型特异性标志物的表达,提示每个 CAF 细胞系均保留了其起源亚型的特征。为研究这些不同 CAFs 如何影响肿瘤细胞侵袭,我们开发了一种 CRC 器官芯片共培养模型。具体而言,该微流控装置模拟与肠道相关的生物力学线索,包括流体流动和类蠕动运动,由两条细胞外基质包被的重叠通道组成,两者之间由多孔膜隔开,允许各腔室之间进行生化和细胞交换。患者来源的 CAFs 和 GFP 标记的 CRC 肿瘤细胞在顶部“上皮”通道中共同培养,而内皮细胞排列于底部“血管”通道。利用延时共聚焦显微镜,追踪和量化侵入血管通道的 GFP+ 肿瘤细胞,从而提供实时侵袭率。当在芯片上将人 CRC 细胞暴露于 CAF 条件培养基和物理共培养中时,我们观察到 CAF 诱导的 CRC 侵袭存在患者特异性差异。有趣的是,一个 myCAF 富集的细胞系仅在物理共培养条件下促进侵袭,提示存在接触依赖性信号。此外,每个 CAF 细胞系在芯片上表现出不同的形态和侵袭模式,其中 myCAF 富集的细胞系在 CRC 细胞之前发生侵袭。总之,这些结果提示可能存在诱导肿瘤侵袭的特定 CAF 表型,这有助于在诊断时洞察原发性 CRC 肿瘤的侵袭潜能。
查看英文原文 English abstract
The influence of the tumor microenvironment (TME) on cancer progression has become a major area of study, driven in part by the continual advances in single-cell and spatial technologies that reveal the TME to be highly heterogeneous. Cancer associated fibroblasts (CAFs), a major component of the tumor stroma, have been classified into several subtypes, each with distinct functionality and influences on the tumor progression. Among these, inflammatory CAFs (iCAFs) and myofibroblastic CAFs (myCAFs) are typically defined by characteristic biomarker profiles and have been shown to have distinct spatial distributions within the tumor. However, the specific functions of these subtypes in contributing to cancer progression, particularly metastasis, is largely unknown. With metastatic disease having poor prognoses, it is vital to elucidate the roles these CAF subtypes play within the metastatic cascade. To address this gap, we have built a diverse biobank of CRC patient-derived tissue samples and matched CAF lines. Single cell RNA-sequencing of patient tissues identified distinct CAF subpopulations. These transcriptional signatures were then applied to bulk RNA-sequencing of the patient-derived CAF lines, which revealed expression patterns consistent with iCAF and myCAF profiles. Flow cytometry and secretome analysis further confirmed expression of subtype-specific markers, suggesting that each CAF line retains features of the originating subtypes.To investigate how these different CAFs influence tumor cell invasion, we developed a CRC organ-on-chip co-culture model. Specifically, this microfluidic device simulates gut-relevant biomechanical cues, including fluid flow and peristalsis-like motion, and is composed of two extracellular matrix-coated overlapping channels separated by a porous membrane, allowing biochemical and cellular exchanges between compartments. Patient-derived CAFs and GFP-labelled CRC tumor cells are cultured together in the top “epithelial” channel, while the endothelial cells line the bottom “vascular” channel. Using time-lapse confocal microscopy, GFP+ tumor cells intravasating into the vascular channel are tracked and quantified, providing real time invasion rates. We observed patient-specific differences in CAF-induced CRC invasion when exposing human CRC cells on-chip to CAF-conditioned media and in physical co-cultures. Interestingly, a myCAF-enriched line promoted invasion in only physical co-culture conditions, suggesting contact-dependent signaling. Additionally, each CAF line displayed distinct morphology and invasion patterns on-chip with the myCAF-enriched line invading before the CRC cells. Collectively, these results suggest that there may be specific CAF phenotypes that induce tumor invasion which could give insight into determining the invasive potential of a primary CRC tumor at diagnosis.
利益披露 Disclosure
B. Haliday, None..
C. Strelez, None..
E. Fung, None..
S. M. Mumenthaler, None.